China

α-Synuclein in Parkinson’s disease and advances in detection

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is a threatening neurodegenerative disorder that seriously affects patients’ life quality. Substantial evidence links the overexpression and abnormal aggregation of alpha-synuclein (α-Syn) to PD. α-Syn has been identified as a characteristic biomarker of PD, which indicates its great value of diagnosis and designing effective therapeutic strategy. This article systematically summarizes the pathogenic […]

α-Synuclein in Parkinson’s disease and advances in detection Read More »

Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial

Diet and Exercise, Herbs & Spices, Parkinson's Disease, Pre-PD, Vitamins / Supplements / Nutraceuticals /

Background Parkinson’s disease (PD) is a prevalent and debilitating condition. Conventional medications cannot control all symptoms and may inflict adverse effects. A survey reported that Chinese herbal medicine (CHM) is frequently sought. Existing CHM trials were contradictory and often of poor quality due to lack of methodological rigor. A national clinical guideline was drafted in

Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial Read More »

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder

A-Synuclein, Probiotics, Prebiotics and Symbiotics /

This study aimed to evaluate the attenuating effect of Lactobacillus plantarum DP189 on α-synuclein (α-SYN) aggregates in the substantia nigra (SN) of Parkinson’s disease (PD) mice via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced. Our results indicated that L. plantarum DP189 increased the levels of superoxide dismutase (SOD), glutathione peroxide (GSH-Px), and interleukin-10 (IL-10) and decreased the levels of malondialdehyde (MDA), reactive oxygen species

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Butyrate, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease

A-Synuclein, Autonmic nervous system, Constipation, ENS, Gut Dysbiosis, iRBD, Non-Motor Symptoms, Orthostatic Hypotension, Parkinson's Disease, Pre-PD /

Braak’s hypothesis has been extremely influential over the last two decades. However, neuropathological and clinical evidence suggest that the model does not conform to all patients with Parkinson’s disease (PD). To resolve this controversy, a new model was recently proposed; in brain-first PD, the initial α-synuclein pathology arise inside the central nervous system, likely rostral to

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease Read More »

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation

Butyrate, Constipation, Pre-PD, Short Chain Fatty Acids /

A variety of opinions exist on the potential of probiotics to provide relief from chronic constipation with much focus placed on their mechanism of action and causes of heterogeneity in the results of different studies. We aimed to determine the efficacy and safety of ingesting Bifidobacterium bifidum (B. bifidum) CCFM16 for 28 days to relieve

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation Read More »

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder

Biomarkers, iRBD, Parkinson's Disease, Pre-PD /

Current study provides a valuable and highly informative dataset of EV-associated sncRNAsfrom plasma of iRBD and PD patients. We identified miRNA signature features that could serve asminimally-invasive, blood-based surveillance biomarkers for distinguishing iRBD or PD from healthyindividuals with high sensitivity, specificity, and accuracy. CLICK TO REVIEW

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder Read More »

Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis

A-Synuclein, Biomarkers, Hyposmia, Hyposmia, iRBD, Orthostatic Hypotension /

Background A number of promising biomarkers for predicting imminent α-synucleinopathies have been suggested in isolated rapid eye movement sleep behaviour disorder (iRBD). However, existing evidence is conflicting without quantitative evaluation. Methods PubMed, Web of Science and ClinicalTrials.gov were searched through June 2021 to identify possible predictors of phenoconversion from iRBD to Parkinson’s disease (PD). The pooled HRs

Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis Read More »

Potential Role of Akkermansia muciniphila in Parkinson’s Disease and Other Neurological/Autoimmune Diseases

Gut Microbiota, Metabolites, Probiotics, Prebiotics and Symbiotics /

The composition of the gut microbiota, including Akkermansia muciniphila (A. muciniphila), is altered in many neurological diseases and may be involved in the pathophysiological processes of Parkinson’s disease (PD). A. muciniphila, a mucin-degrading bacterium, is a potential next-generation microbe that has anti-inflammatory properties and is responsible for keeping the body healthy. As the role of A. muciniphila in PD has

Potential Role of Akkermansia muciniphila in Parkinson’s Disease and Other Neurological/Autoimmune Diseases Read More »

Bioactive lipids and their metabolism: new therapeutic opportunities for Parkinson’s disease

A-Synuclein, Dementia - Lewy Bodies, Non-Motor Symptoms, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is a neurological disorder characterized by motor dysfunction, which can also be associated with non-motor symptoms. Its pathogenesis is thought to stem from a loss of dopaminergic neurons in the substantia nigra pars compacta and the formation of Lewy bodies containing aggregated α-synuclein. Recent works suggested that lipids might play a pivotal

Bioactive lipids and their metabolism: new therapeutic opportunities for Parkinson’s disease Read More »